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Abstract
Background:  Complex Regional Pain Syndrome type one (CRPS I) or formerly Reflex
Sympathetic Dystrophy (RSD) is a disabling syndrome, in which a painful limb is accompanied by
varying symptoms. Neuropathic pain is a prominent feature of CRPS I, and is often refractory to
treatment. Since gabapentin is an anticonvulsant with a proven analgesic effect in various
neuropathic pain syndromes, we sought to study the efficacy of the anticonvulsant gabapentin as
treatment for pain in patients with CRPS I.
Methods: We did a randomized double blind placebo controlled crossover study with two three-
weeks treatment periods with gabapentin and placebo separated by a two-weeks washout period.
Patients started at random with gabapentin or placebo, which was administered in identical capsules
three times daily. We included 58 patients with CRPS type 1.
Results: Patients reported significant pain relief in favor of gabapentin in the first period. Therapy
effect in the second period was less; finally resulting in no significant effect combining results of both
periods. The CRPS patients had sensory deficits at baseline. We found that this sensory deficit was
significantly reversed in gabapentin users in comparison to placebo users.
Conclusions: Gabapentin had a mild effect on pain in CRPS I. It significantly reduced the sensory
deficit in the affected limb. A subpopulation of CRPS patients may benefit from gabapentin.
Background
Complex Regional Pain Syndrome type one (CRPS I) or
formerly Reflex Sympathetic Dystrophy (RSD) is a disa-
bling syndrome, in which a painful limb is accompanied
by varying symptoms like edema, hyperhidrosis, hypertri-
chosis, allodynia, coloring of the skin and, over time, atro-
phy of the involved tissue. Spontaneous recovery does
occur and several therapies have been described, but for
some patients CRPS I is a chronic disabling disease[1].
Neuropathic pain is a prominent feature of CRPS I, occur-
ring in 75% of cases[1], and many researchers go as far as
classifying CRPS I as a neuropathic pain syndrome [2-6].
Gabapentin (Neurontin®, Pfizer) is an anticonvulsant
with a proven analgesic effect in various neuropathic pain
syndromes [7-15]. Anecdotal reports suggest that gabap-
entin may also be an effective analgesic in CRPS
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patients[3,8,16-27]. To study this hypothesis, we con-
ducted a double blind, placebo-controlled crossover trial




This study complied with the Declaration of Helsinki
regarding investigations in humans after approval of the
protocol by the Institutional Review Board of the Univer-
sity Hospital Maastricht, the Netherlands. Patients were
recruited from a database with patients who, in recent
years, had been diagnosed with complex regional pain
syndrome type I in our hospital. All patients had been
treated in our pain management and research center
(dept. of Anesthesiology, University Hospital Maastricht,
The Netherlands) and had received sympathetic
blocks[28], mannitol infusions[29,30], and transcutane-
ous neuromodulation[31]. All participating patients ful-
filled the IASP criteria[32] for the diagnosis of CRPS type
I and were included if they were between 18 – 75 years old
and had a score for pain > 3, as rated on a visual analog
score (VAS), where 0 is no pain and 10 is the worst pain
imaginable. Apart from IASP criteria, all patients had
functional loss and pain outside the original traumatized
area. Patients were excluded in case of a possibility of
health risk or confounding by other diseases of syn-
dromes, like e.g., pregnancy, known kidney and/or severe
liver disease, another (2nd) chronic pain syndrome,
known nerve damage in the affected area, active infection
or diabetes mellitus. Patients were participating in 8-week
periods from 19-11-1998 until 2-12-1999. Gabapentin
was not registered as a drug in the Netherlands before or
during the trial. After the trial the producing pharmaceu-
tical company supplied gabapentin for compassionate use
if indicated.
Treatment
Since our patient population consisted of chronic CRPS I
patients with a multiple years' duration of pain com-
plaints refractory to various treatments, we assumed that
their pain complaints would be more or less stable. We
therefore undertook a double blind, randomized crosso-
ver study. Randomization of patients took place after
baseline measurements and written informed consent.
The assignment scheme was generated by our hospital
pharmacy from a table of random numbers. The closed
envelopes containing the assignments were prenumbered
and kept at the pharmacy. The first treatment group
received gabapentin, followed by a washout period and
placebo treatment. The second treatment group received
placebo treatment, which was followed by a washout
period and gabapentin treatment. Each medication period
lasted three weeks separated by the two-weeks washout
period. Medication was stocked and delivered to the
patient at the hospital pharmacy. Both the gabapentin
capsules and the identical placebo capsules were delivered
immediately before the start of the two medication peri-
ods. Left over medication was recollected and counted.
The gabapentin (GBP) dose was slowly increased to
reduce adverse side effects:
600 mg's GBP AN once a day on day 1–2
600 mg's GBP b.i.d. on day 3–4
600 mg's GBP t.i.d on day 5–21
Placebo dose was identically titrated. Patients were
allowed to take their usual analgesics and were told pref-
erably not to change the usual dose.
Follow-up measurements
The patients were reevaluated at the hospital three weeks
(T1), five weeks (T2) and eight weeks (T3) after randomi-
zation. During the trial, the patient noted her/his pain rate
of the past 24 hr (VAS) and the use of additional analge-
sics in a diary. During each hospital visit the following
assessments were done:
1. Global perceived effect (GPE) on pain indicating: worst
ever; much worse; somewhat worse; not improved/not
worse; somewhat improved; much improved and best
ever. GPE on function was scored on an analogous scale.
2. Neuropathic pain scale (NPS), a 10 item qualitative
evaluation of neuropathic pain[33].
3. Sensibility through Von Frey monofilament skin appli-
cation each on 9 areas corresponding to cutaneous nerve
branches and dermatomes of either both hands or both
feet[34]. Stimulus placement of filaments was as follows:
one second for placement, one second for bending and
one second for removal. (handset with resp. 0.0677,
0.4082, 2.052 and 3.632 grams calculated force, North
Coast Medical, Inc., San José, USA).
4. Mechanic allodynia test with brush strokes and static
pressure with the finger tip[35], on 9 areas corresponding
to cutaneous nerve branches and dermatomes of either
both hands or both feet.
5. Edema, discoloration, and changed skin temperature
were scored after physical examination on a three point
scale indicating no, some or overt presence of each sign,
the latter two signs in comparison to the healthy or
healthiest limb. Physical examination in CRPS is well
comparable to instrumental evaluation of signs with vol-
umeter, infrared thermometer and goniometer[36].BMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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6. Impairment and disability tests: Symptom Checklist-
90-Revised (SCL-90-R)[37], Brief Pain Inventory[38],
adapted for CRPS to measure the influence of CRPS in
general on daily life by 0–10 scale ranging from 0 ('CRPS
has not interfered') to 10 ('CRPS completely interfered'),
'range of motion' as a parameter of limb function.
Side effects during treatment
A blinded independent investigator (STvdB) did sensibil-
ity, allodynia and range of motion tests (see above). A
physician (AvdV), who examined each patient, did all the
other measurements throughout the trial. Patient, investi-
gator and physician were unaware of the treatment
received. We tested blinding by questioning physician and
participants after each medication period.
Statistical analysis
The statistical analysis of VAS-scores was determined per
patient using estimating medication and period effect
through linear regression analyses. Possible relationship
of patient characteristics and outcome was tested by Pear-
son R's test. Mann-Whitney analyses were used for mono-
filament sensitivity on log-transformed data. Three point
scales and seven point scales were dichotomized and like
the SCL-90-R, NPS and CRPS-Brief Inventory question-
naires intra-individual paired tested (McNemar, t-test,
Bonferroni-Holm corrected for multiple tests). Student t-
tests and regression analysis were used to test treatment
effect, which is calculated in crossover studies as ((AT1-
AT0)-(AT3-AT2))/2+((BT3-BT2))-BT1-BT0)/2, where A
represents data of placebo starters and B data of gabapen-
tin starters both before (T0,T2) and after (T1,T3) treat-
ments[39]. Blinding was tested with Chi-square analyses.
Possible related factors to therapy effect were analyzed
with forward stepwise logistic regression. Data analyses
required complete data sets. Patients who were not com-
pleting one or two treatments were excluded for analyses.
We tested two-tailed, with α = 0.05 as a level of signifi-
cance (Excel 2000, SPSS 10.0 for Windows).
Results
Demographics
After randomization 58 patients were enrolled, with a
mean age of 44.0 (range 24–75) resulting in 29 patients in
the gabapentin-placebo arm and 29 patients in the pla-
cebo-gabapentin arm; 49 patients completed the gabap-
entin period, 50 patients the placebo period, 46 patients
completed both periods and were used for further within-
patient paired analysis (Fig. 1). Twelve patients discontin-
ued treatment of which 6 during the placebo treatment, 2
during washout and 4 during GBP treatment. Three of
these four GBP users discontinued due to side effects (Fig.
1). Between randomization and start of (placebo) medica-
tion one patient withdrew after rereading the information
letter about possible side effects. These patients were
excluded from analysis, since intra-individual testing was
necessary for most of the data-analyses. Patients, who
could not be used for analysis, did not differ in their char-
acteristics from the total group nor comparing between
the two arms of treatment (Tables 1 and 2). When com-
paring the placebo-GBP arm and GBP-placebo arm on
sexes, age and pain level before period 1 or 2, duration of
illness, SCL-90-R score, we could not find a difference
between the two arms (Tables 1 and 2). SCL-90-R score
revealed increased values on any subscale comparing to
standard norms, indicating personal distress (Table 2).
We found relative higher scores on somatic and sleeping
complaints. The SCL-90-R scores were identical to control
chronic pain patients (N = 143), besides higher score on
sleeping complaints (T. Forouzanfar, data not published).
Trial medication was returned and counted afterwards,
but revealed no lack of compliance in any patient.
Blinding
After each medication period both patient and physician
were asked about their ideas concerning study medication
in the past period. The treating physician guessed the used
medication correctly more often after both phases than
can be explained by coincidence (p = 0.000). Blinding for
patients was sufficient in the first phase, but not anymore
after the second phase (p = 0.2 versus p = 0.000).
Response to treatment
Pain
Comparing gabapentin and placebo users in terms of pain
relief, there was a significant pain relief in favor of gabap-
entin in the first period. Therapy effect in the second
period was less, finally resulting in no significant effect
combining results of both periods. There was an unex-
pected increase of pain level above baseline in the wash-
out period for both the gabapentin starters and placebo
starters (Figure 2).
Global perceived pain relief as measured by the seven-
point scale showed a significant effect for gabapentin, and
also more pronounced in the first period. This measure-
ment also found a significant effect in the second period,
with an effect being defined as a patient scoring 'much
improvement'. Statistical analysis of global perceived
effect showed significant more treatment effect (p =
0.002) with 43 % versus 17 % reported pain relief respec-
tively during gabapentin compared to placebo treatment.
13 % of patients reported aggravation of pain during
gabapentin vs. 9 % during placebo treatment (Figure 3
and table 3). Stepwise forward logistic regression analysis
of baseline value of pain level, age, sex, duration of illness,
location of illness, mono- or bilateral CRPS, trial arm and
all items of CRPS-BI, NPS and SCL-90-R was performed.
Only the level of self care was related to perceived pain
relief during GBP. The neuropathic pain scale, indicatingBMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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Selection of patients participating in the trial Figure 1
Selection of patients participating in the trial
Filescreening (n=188) 
Not invited for screening (n=37) 
Screened (n=151)
Not  randomized (n=93) 
withdrew consent (n= 41 ) 
other signif. diagnosis (e.g. CRPS II, (n= 20 ) 
age (n= 5 ) 
insufficient pain score (n= 14 ) 
other criteria (n= 13 ) 
Randomized (n=58) 
withdrawn (n=12)        placebo GBP   wash-out
adverse effects (n= 3)                          0          3       0 
treatment failure (n= 0)  0 0 0
illness (n=1) 1 0 0 
lost to follow up (n= 2 )  2 0 0
wanted to drive car (n= 3)  2 1 0
holiday trip (n=1)  1 0 0
personal reasons (n=1) 0 0 1 
start other treatment (n=1)  0 0 1BMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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different aspect of pain, improved significantly in terms of
less hot and more comfortable, but not when corrected for
multiple tests (Bonferroni-Holm correction). We found
that during gabapentin use, patients reported equal use of
co-medication comparing to baseline assessment and pla-
cebo-use with a non-significant trend towards less medi-
cation during GBP use.
Sensory tests
Each participant was tested throughout the study on
response to mechanical stimuli with von Frey filaments.
The CRPS patients had sensory deficits at baseline. Appli-
cation of smaller filaments was not felt in multiple skin
areas. We found, with Mann-Whitney analyses, that this
sensory deficit was significantly reversed in gabapentin
users in comparison to placebo users (p = 0.027). This dif-
ference was found in patients with upper and lower
extremity CRPS, but was still significant in the subgroup
of lower extremity CRPS (p = 0.011) as seen in table 4.
Mechanical allodynia to static and dynamic stimuli (soft
touch and brush) was measured by a mean of 11-point
Table 1: Patient characteristics
Placebo starter GBP starter
Excluded from analysis
Placebo starter GBP starter
N = 24 N = 22 N = 5 N = 7
Sex (F/M) 21/4 18/4 3/2 6/1
Age in years 42 (± 13) 47 (± 14) 40 (± 11) 43 (± 11)
Duration in months 43 (± 36) 44 (± 21) 83 (± 39) 45 (± 30)
VAS0 64.2 (± 16) 62.5 (± 18) 62 (± 10) 67 (± 12)
VAS2 67 (± 20) 64(± 21)
Upper extremity in pain 3R 8L 3RL = 14 8R 7L 4RL = 18 2R 0L 1RL 2R 4L 0RL
Lower extremity in pain 2R 7L 4RL = 13 3R 3L 0RL = 6 2R 1L 0RL 1R 1L 1RL
R/L/RL represents no. of patients that report pain in resp. right, left or bilateral extremities.
A few patients had upper and lower extremity pain. VAS is pain level on visual analogue scale. VAS0 is day 1, VAS2 is day 21 (post wash-out). Data are mean 
with (SD)
Table 2: Basic characteristics of participating patients on neuropathic pain scale (NPS), CRPS brief inventory and SCL-90-R. Data are 
mean with (± standard deviation).
NPS Intensity Sharpn. Hot Aching Cold Sens. Itch. Comfo. Deep p. Superf.P.
Mean N = 24 7,3 (± 1,8) 7,3 (± 1,5) 6,0 (± 3,2) 7,0 (± 2,4) 6,0 (± 3,2) 6,6 (± 2,5) 2,8 (± 2,5) 7,8 (± 1,6) 7,6 (± 1,3) 6,0 (± 2,7)
Mean N = 22 7,3 (± 1,4) 7,4 (± 1,5) 5,9 (± 3,1) 7,2 (± 1,6) 5,9 (± 3,1) 7,2 (± 2,5) 3,7 (± 3,1) 7,7 (± 1,4) 7,8 (± 1,2) 6,8 (± 2,4)
Lost ABN = 5) 7,6 (± 0,5) 8 (± 1,2) 6,2 (± 3,8) 6,8 (± 1,8) 8,2 (± 0,8) 8,4 (± 0,9) 2,8 (± 3,8) 7,3 (± 1,7) 8,2 (± 1,3) 7,4 (± 1,1)
Lost N = 7 7,7 (± 1,4) 7 (± 1,3) 5,7 (± 3,3) 8,3 (± 1,0) 8,4 (± 1,7) 8,6 (± 1,1) 2,3 (± 2,9) 8,8 (± 1,0) 8,3 (± 1,1) 8,6 (± 0,8)
SCL-90-R anxiety fobic depression somatiz Obs-comp sensitivity hostility insomnia psneu
Total AB (n = 24) 15,9 (± 5,8) 10,9 (± 4,0) 31,1 (± 11,4) 26,2 (± 8,3) 19,2 (± 7) 26,8 (± 10,1) 10,2 (± 5,4) 10,1 (± 3,9) 163,0 (± 47,5)
Total BA (n = 21) 15,9 (± 5,8) 11,2 (± 6,3) 33,6 (± 14,4) 25 (± 8) 19,7 (± 6,0) 28,1 (± 10,5) 8 (± 1,9) 10,3 (± 3,5) 163,8 (± 44,9)
Lost AB (n = 5) 18,4 (± 11,2) 13,4 (± 8,3) 27,8 (± 10) 26,8 (± 7,8) 21 (± 2,9) 26 (± 2) 9,2 (± 2,8) 11,6 (± 2,1) 166,8 (± 41,2)
Lost BA (n = 6) 19,7 (± 11,1) 12,2 (± 4,4) 33 (± 17,5) 29,17 (± 11,5) 22,3 (± 9,8) 33,5 (± 18,0) 11,7 (± 7,5) 12,8 (± 2,1) 189,7 (± 80,1)
CRPS brief inventory= == = == === =
1 2 3 4 5 6 7 8 9 10
Mean N = 24 7,4 (± 1,7) 6,5 (± 2,1) 6,3 (± 3,1) 7,6 (± 2,0) 4,2 (± 2,6) 7,0 (± 2,8) 6,4 (± 2,2) 4,3 (± 3,4) 7,2 (± 2,2) 5,6 (± 2,5)
Mean N = 22 7,0 (± 2,0) 5,0 (± 3,0) 6,3 (± 3,0) 7,8 (± 2,3) 4,8 (± 2,9) 7,7 (± 2,1) 5,1 (± 3,1) 5,1 (± 2,7) 6,8 (± 2,5) 5,5 (± 2,5)
Lost AB n = 5 7,4 (± 1,8) 7,2 (± 1,6) 7,8 (± 0,4) 9 (± 1) 4,6 (± 1,5) 8,2 (± 0,8) 6 (± 2,6) 6,4 (± 2,6) 7,2 (± 3,6) 6,8 (± 1,1)
Lost BA n = 7 8,6 (± 1,4) 6 (± 3) 6,4 (± 3,9) 9 (± 1,2) 5 (± 2,9) 8 (± 1,6) 7 (± 2,8) 6,7 (± 1,8) 7,3 (± 2,3) 6,6 (± 2,4)
NPS description of pain in terms of 1. intensity 2. sharpness 3. hot 4. aching 5. cold 6. sensitive 7. itching 9. comfortability 10a. intensity deep pain 10b. 
intensity superficial pain. Item 8 is a nominal scale left out of analysis.
Symptom Checklist-90-Revised (SCL-90-R) subscale on anxiety, phobic anxiety, depression, somatization, obsessive compulsive, interpersonal sensitivity, 
hostility, insomnia and psycho neuroticism.
CRPS BI: influence of CRPS on 1. general activity 2. mood 3. mobility 4. normal work 5. personal relationships 6. sleep 7. enjoyment of life 8. self care 9. 
recreational hobbies 10. social activities. CRPS BI and NPS on a 0–10 scaleBMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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scales (range 0–10) of 9 areas of the hand/feet corre-
sponding to cutaneous nerve branches. We found no
effect of gabapentin on allodynia in comparison to
placebo.
Other symptoms
No difference was found on the parameters edema, discol-
oration, range of motion of wrist/ankle and fingers/toes
between placebo and GBP. 10 patients out of 45
improved in relative skin temperature during placebo use
compared to 18 patients out of 45 in gabapentin, which is
two sided tested not significantly different (McNemar
analysis, p = 0.096).
Limb dysfunction and quality of life
The reported function improvement was, with 10 positive
responders during GBP versus 7 positive responders dur-
ing placebo, not significantly different (N = 46) between
the two treatments. The SCL-90 showed no significantly
better scores during gabapentin treatment. CRPS-BI
showed improvement of sleep between placebo treatment
and gabapentin treatment., but this effect disappeared
after Bonferroni-Holm correction.
Adverse effects
Dizziness, somnolence and lethargy were significantly
more often reported during gabapentin use than during
placebo. Before washout 95 % of patients (n = 21)
reported side effects during gabapentin use versus 58 % in
placebo treatment (n = 14). After washout this was respec-
tively 63% (n = 15) in GBP and 32% (n = 7) in placebo
use. For more details on side effects see table 6. Since a
high incidence of side effects can produce a stronger pla-
cebo effect, we analyzed the possible correlation between
side effects and pain relief. There was a small relation
between perceived side effects and pain relief in placebo
users in period 2 (p = 0.04, Pearson's R value is 0.4), but,
whether in period 1 or period 2, no relationship was
found during the use of gabapentin (p = 0.2 in period 1, P
= 0.4 in period 2).
Discussion
To evaluate gabapentin treatment as a treatment for pain
in CRPS, we conducted a placebo-controlled crossover
study. We conclude from our trial that overall, gabapentin
did not relieve pain as compared to placebo on pain visual
analogue scores, our primary outcome measure.
Gabapentin relieved pain in a subgroup of patients and
gave a significant global perceived pain relief. The effect
was mild and there was no patient in which gabapentin
completely eliminated pain. Moreover, the frequency of
side effects as dizziness, somnolence and lethargy was
higher during gabapentin treatment than with placebo.
These side effects probably also account for the relative
lack of blinding we observed in our study. This does not
mean that the study was biased: our population was
chronic CRPS patients who all had undergone numerous
unsuccessful treatments, and clearly wanted the drug to
work. Any possible bias would therefore have been posi-
tive towards gabapentin.
VAS for pain in both groups at start (T0), three weeks (T1),  five weeks (T2), and eight weeks (T3) after randomization Figure 2
VAS for pain in both groups at start (T0), three weeks (T1), 
five weeks (T2), and eight weeks (T3) after randomization. 
T0-1 is the first treatment period, and T2-3 the second
Global perceived pain relief (on a seven-point scale) as  reported by patients Figure 3
Global perceived pain relief (on a seven-point scale) as 
reported by patients. GBP-1 and -2 denote patients receiving 
GBP in the first and second period; placebo-1 and -2 are 
analogously denoted.BMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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Although we did not find a significant pain reducing effect
when analyzing the complete trial, we did find a signifi-
cant effect in the first half of the trial. In fact, the difference
in outcome between the two trial halves is striking. There
was a reverse carry-over effect resulting in increasing pain
above baseline after the washout period for both gabapen-
tin and placebo starters. The increase of pain intensity
above baseline level in the second period (before the start
of placebo treatment) cannot be explained pharmacolog-
ically. Gabapentin has no known biological dependency
or tolerance mechanism. It can be a period effect,
although this would more likely result in a regression to
the middle instead of increasing pain. Perhaps this is a
reversed placebo effect in which the expectation and/or
the actual perception of not receiving gabapentin any-
more might increase pain intensity. Kemler and de Vet
found that treatment allocation in a trial could influence
pain intensity in CRPS[40]. The decreasing therapy effect
after washout is found in other crossover pain trials[41].
Expectation and attention have been shown to be power-
Table 3: Patients (%) with global perceived effect on pain in the four arms of treatment and totals for the two treatments.
Treatment period GBP-1= Placebo-1= Wash-out= GBP-2= Placebo-2=
% some improvement (n) 45% (10) 13% (3) 1 8% (2) 13% (3)
% much improvement (n) 14% (3) 5% (1) 0 21% (5) 4% (1)
% total (n/N) 59% (13/22) a 17% (4/24) 1 29% (7/24) 18% (4/22)
= Total = GBP = = Total = placebo = = =
% some improvement 26% (12/46) 13% (6/46)
% much improvement 17% (8/46)β 4% (2/46)
% total (n/N) 43% (20/46)a 17% (8/46)
worsened 13% (6/46) 9% (4/46)
GBP-1 is gabapentin treatment before wash-out. GBP-2 is gabapentin treatment after wash-out. 'α' is significant, P < 0.005, 'β' is P < 0.10 McNemar two sided 
tested gabapentin versus placebo.
Table 4: Mann-Whitney scores of monofilament application in CRPS patients testing cutaneous sensibility thresholds
Mean ranking
Hand Feet Total
Placebo 12.0 (N = 12) 5.5 (N = 10) 16.8 (N = 22)
Gabapentin 15.6 (N = 15) 12.0*(N = 3) 25.0*(N = 18)
Significant different values (p < 0.05) are marked with*.
Table 5: Side effects as mentioned after treatment
Adverse effect Gabapentin (N = 54) n (%) Placebo (N = 51) n(%) Significance
Dizziness 20 (37.3) 2 (3.9) P = 0.0000
Somnolence 15 (27.8) 3 (5.9) P = 0.003
Lethargy 11 (20.4) 1 (2.0) P = 0.003
Nausea 10 (18.5) 5 (9.8) n.s.
Headache 8 (14.8) 3 (5.9) n.s.
Stomach problems 4 (7.4) 3 (5.9) n.s.
'drunken' 4 (7.4) 0 (0) n.s.
Disturbed gait 4 (7.4) 0 (0) n.s.
Water retention 1 (1.9) 3 (5.9) n.s.
Data on all patients who started treatment and returned for assessment after 3 weeks, with or without completing 3 weeks of treatment. n.s. is 'not significant'BMC Neurology 2004, 4:13 http://www.biomedcentral.com/1471-2377/4/13
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ful influences on pain pathways in the brain[42], and per-
haps a crossover design is not suited to study treatments
in chronic pain patients.
We found a decreased sensory deficit in gabapentin users
compared to placebo users. We did not expect this, but
found in the literature several cases in which gabapentin
decreased the area of hypesthesia in neuropathic pain syn-
dromes[43]. This has, to our knowledge, never been
described for any other medication. Numbness or
mechanical hypesthesia is a frequently found complaint
for approximately 75 % of CRPS patients, which can
improve in time spontaneously and after placebo treat-
ment[44]. It is possible that the somatosensory findings
and pain outside the original area of trauma can be attrib-
uted to referred pain mechanisms. Gabapentin has been
reported to alleviate referred pain[45]. Since many CRPS
patients have mechanical hypesthesia, we hypothesize
that gabapentin influences some common neural
pathway for 'referred' sensations, whether mechanical
sensation or pain.
Conclusions
Gabapentin had a mild effect on pain in patients CRPS I.
It significantly reduced the sensory deficit in the affected
limb. A subpopulation of CRPS patients may benefit from
gabapentin, but then for each individual patient the ben-
efit has to be weighed against the frequently occurring
side effects.
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